MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q3
hinzugefügt 08.11.2022
Albireo Pharma ROE 2011-2026 | ALBO
ROE Jährlich Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -19.38 | -59.39 | -67.32 | -37.6 | -37.41 | -52.03 | -47.37 | -61.99 | -59.38 | -66.89 | -28.57 |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -19.38 | -67.32 | -48.85 |
ROE Vierteljährlich Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -101.55 | -70.14 | -0.95 | 2.11 | -30.24 | -47.2 | -95.58 | -74.86 | -45.71 | -69.22 | -75.78 | -82.26 | -59.25 | -70.68 | -58.6 | -52.66 | -24.67 | -34.64 | -33.19 | -30.74 | -29.67 | -40.57 | -41.5 | -26.25 | -13.88 | 22.9 | -5.39 | -27.52 | -30.7 | 134.02 | 121.26 | 123.54 | 110.66 | -98.87 | -49.41 | -94.73 | -77.41 | -81.21 | -97.66 | -105.18 | -110.83 | -112.46 | -82.36 | -486.87 | -487.18 | 11.15 | -471.4 | -13.46 |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 134.02 | -487.18 | -64.93 |
ROE anderer Aktien in der Pharmaeinzelhändler
| Name | ROE | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
6.05 | $ 20.29 | -1.98 % | $ 2.56 B | USA |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 0.8 | -5.3 % | $ 4.36 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
-207.46 | $ 166.0 | -0.23 % | $ 8.26 B | USA |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
10.1 | $ 8.59 | -1.66 % | $ 1.4 B | Britain |
 |
Certara
CERT
|
-0.15 | $ 7.22 | 2.34 % | $ 1.16 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
22.46 | $ 23.78 | -0.42 % | $ 2.91 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-69.87 | $ 18.17 | 1.57 % | $ 873 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-6.05 | $ 17.9 | -1.38 % | $ 459 M | USA |
 |
Exelixis
EXEL
|
36.21 | $ 40.5 | -1.29 % | $ 11 B | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Galectin Therapeutics
GALT
|
44.9 | $ 2.89 | -5.56 % | $ 180 M | USA |
 |
Capricor Therapeutics
CAPR
|
-98.61 | $ 26.3 | -2.08 % | $ 704 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-97.53 | $ 1.02 | -0.33 % | $ 74.9 M | USA |
 |
Galapagos NV
GLPG
|
-11.44 | $ 33.13 | -2.82 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
-623.07 | $ 27.88 | 1.79 % | $ 363 M | USA |
 |
Galecto
GLTO
|
-118.61 | $ 29.63 | -1.41 % | $ 787 M |  Danmark |
 |
Genmab A/S
GMAB
|
24.88 | $ 27.66 | -6.71 % | $ 17.7 B | Danmark |
 |
Halozyme Therapeutics
HALO
|
649.18 | $ 68.58 | -1.82 % | $ 8.22 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
Hoth Therapeutics
HOTH
|
-119.04 | $ 1.0 | -1.47 % | $ 6.38 M | USA |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Harmony Biosciences Holdings
HRMY
|
18.24 | $ 28.32 | -2.01 % | $ 1.63 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
ImmuCell Corporation
ICCC
|
-7.84 | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
160.57 | $ 3.27 | -2.1 % | $ 1.17 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-34.6 | $ 28.57 | -2.16 % | $ 1.66 B | USA |
 |
Immuron Limited
IMRN
|
-12.31 | $ 0.75 | -0.69 % | $ 6.46 M |  Australia |
|
Immatics N.V.
IMTX
|
1.79 | $ 10.09 | 1.0 % | $ 635 M | Germany |
 |
Immunic
IMUX
|
1456.2 | $ 1.13 | 6.61 % | $ 176 M | USA |
 |
Immunovant
IMVT
|
-58.5 | $ 27.09 | -2.38 % | $ 4.11 B | USA |
 |
Inhibrx
INBX
|
-554.81 | $ 76.39 | -1.42 % | $ 3.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
-65.74 | $ 0.8 | -2.44 % | $ 1.96 M | Canada |